Skip to main content

NEW YORK (TheStreet) -- AstraZeneca  (AZN) - Get Astrazeneca PLC Sponsored ADR Report stock is up by 0.06% to $34.10 in midday trading on Monday, after the British bio-pharmaceutical company sold its Crohn's disease treatment to PerrigoCompany (PRGO). 

Healthcare supplier Perrigo will pay AstraZeneca $380 million for the rights to sell AstraZeneca's gastroenterology medicine, Entocort, for patients with Crohn's disease.

AstraZeneca said the medicine area was outside of its strategic focus. 

"Our agreement with Perrigo completes the global divestment of Entocort, emphasising our strategic focus on three main therapy areas and providing further simplification of our supply chain," AstraZeneca Executive VP Luke Miels said in a statement. "We are pleased to be working with Perrigo to ensure patients with Crohn's disease in the US continue to benefit from this important medicine."

U.S. sales of Entocort were $89 million year-to-date.

TheStreet Recommends

Separately, TheStreet Ratings team rates ASTRAZENECA PLC as a Hold with a ratings score of C+. TheStreet Ratings Team has this to say about their recommendation:

We rate ASTRAZENECA PLC (AZN) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and weak operating cash flow.

Highlights from the analysis by TheStreet Ratings Team goes as follows:

  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Pharmaceuticals industry. The net income increased by 203.1% when compared to the same quarter one year prior, rising from $254.00 million to $770.00 million.
  • The debt-to-equity ratio is somewhat low, currently at 0.63, and is less than that of the industry average, implying that there has been a relatively successful effort in the management of debt levels.
  • ASTRAZENECA PLC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, ASTRAZENECA PLC reported lower earnings of $0.49 versus $1.02 in the prior year. This year, the market expects an improvement in earnings ($2.10 versus $0.49).
  • Net operating cash flow has decreased to $1,745.00 million or 10.51% when compared to the same quarter last year. In conjunction, when comparing current results to the industry average, ASTRAZENECA PLC has marginally lower results.
  • AZN has underperformed the S&P 500 Index, declining 9.77% from its price level of one year ago. Looking ahead, we do not see anything in this company's numbers that would change the one-year trend. It was down over the last twelve months; and it could be down again in the next twelve. Naturally, a bull or bear market could sway the movement of this stock.
  • You can view the full analysis from the report here: AZN

Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of Jim Cramer, TheStreet or any of its contributors.